Gliomas: Difference between revisions

From NeuroWiki
Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{NoteBox|secondary}}<strong>Related pages</strong>
* [[Molecular markers in Gliomas]]
{{NoteBoxEnd}}
= WHO 2016 Classification of Infiltrating Gliomas =
= WHO 2016 Classification of Infiltrating Gliomas =
<table class="wikitable">
<table class="wikitable">
Line 28: Line 32:
     </tr>
     </tr>
     <tr>
     <tr>
       <td>Glioblastoma, IDH-mutant (WHO grade IV)</td>
       <td>[[Glioblastoma]], IDH-mutant (WHO grade IV)</td>
       <td></td>
       <td></td>
     </tr>
     </tr>
Line 72: Line 76:


= High Grade Glioma =
= High Grade Glioma =
<hr>
= Prognostic Factors =
{{NoteBox|secondary}}The data from the pre-IDH era indicated a <u>poorer prognosis</u> associated w/ the following factors:
* >40 y/o (most sig. unfavorable factor)
* Hx of astrocytoma
* SOL ≥6 cm
* Crossing the midline
* Preexisting deficit preQx {{NoteBoxEnd}}


[[Category:Neuro-Oncology]]
[[Category:Neuro-Oncology]]

Latest revision as of 04:07, 5 March 2024

WHO 2016 Classification of Infiltrating Gliomas

Diagnosis Common Mutations Additional Characteristics
Astrocytoma
Diffuse astrocytoma, IDH-mutant (WHO grade II)
  • IDH1/IDH2
  • ATRX
  • TP53
  • TERT promoter
  • EGFR amplification
  • +7/−10
  • PTEN mutation/loss
  • H3.3 p.K27M
Usually younger patients (40–50 years old); present as lower gliomas; most glioblastomas in this group are secondary
Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Glioblastoma, IDH-mutant (WHO grade IV)
Diffuse astrocytoma, IDH-wildtype (WHO grade II) Usually older patients (>55 years old); present as high-grade gliomas; most glioblastomas in this group are primary
Anaplastic astrocytoma, IDH-wildtype (WHO grade III)
Glioblastoma, IDH-wildtype (WHO grade IV)
Diffuse midline glioma, H3 -K27M-mutantMidline location, infiltrating on histology, H3.3 p.K27M mutation
Oligodendroglioma
Oligodendroglioma, IDH-mutant, 1p/19q codeleted (WHO grade II) IDH1/IDH2
1p/19q codeletion
ATRX is wild-type (ATRX mutations are mutually exclusive with 1p/19q codeletion), strong correlation with perinuclear clearing histology
Anaplastic oligodendroglioma, IDH-mutant, 1p/19q codeleted (WHO grade III)

Low Grade Glioma

Outlines from Neurosurgery Self-assessment - Q&A

  • 1° goal in initial Tx of LGG is max. safe resection → assoc. w/ prolonged survival, sz pPx, ↓ risk of transformation;
  • Qx for suspected LGGs challenges:
    • GTR is difficult d/t the diffusely infiltrative growth pattern of LGG → difficult to id the exact tumor borders; ∴ image guidance w/ FLAIR is crucial.
    • Histopathological undergrading is common w/ Bx, as LGG often exhibits focal areas of malignant transformation (anaplastic foci). To avoid this and reduce subsequent treatment failure, the surgical goal is to perform precise tissue sampling from a potential anaplastic focus.
    • "Eloquent" localization → awake Qx ± functional mapping

High Grade Glioma


Prognostic Factors

The data from the pre-IDH era indicated a poorer prognosis associated w/ the following factors:
  • >40 y/o (most sig. unfavorable factor)
  • Hx of astrocytoma
  • SOL ≥6 cm
  • Crossing the midline
  • Preexisting deficit preQx